Champlain Investment Partners LLC Has $50.72 Million Holdings in Omnicell, Inc. $OMCL

Key Points

• Champlain Investment Partners LLC reduced its holdings in Omnicell, Inc. by 1.5%, selling 22,837 shares and retaining approximately 1,450,802 shares, which is valued at about $50.7 million.
• During the first quarter, several other institutional investors, including Diversified Trust Co and EntryPoint Capital LLC, adjusted their stakes in Omnicell, indicating a dynamic investment landscape around the company.
• Omnicell reported earnings per share of $0.45 for the latest quarter, surpassing expectations, with a projected FY 2025 EPS guidance range of $1.400-$1.650.

Champlain Investment Partners LLC lowered its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 1.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1,450,802 shares of the company's stock after selling 22,837 shares during the period. Champlain Investment Partners LLC owned about 3.10% of Omnicell worth $50,720,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Johnson Financial Group Inc. purchased a new position in shares of Omnicell in the fourth quarter worth about $37,000. Point72 Hong Kong Ltd purchased a new position in shares of Omnicell during the fourth quarter worth about $101,000. Corton Capital Inc. purchased a new stake in shares of Omnicell in the fourth quarter valued at about $208,000. Caption Management LLC purchased a new stake in shares of Omnicell in the fourth quarter valued at about $223,000. Finally, AlphaQuest LLC increased its holdings in shares of Omnicell by 79.0% in the 1st quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock valued at $224,000 after purchasing an additional 2,824 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMCL has been the topic of several recent analyst reports. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Benchmark cut their price objective on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler cut their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Finally, Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Omnicell has an average rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Stock Down 2.1%

OMCL traded down $0.69 during trading on Monday, hitting $32.59. The company had a trading volume of 595,171 shares, compared to its average volume of 569,766. The company has a market capitalization of $1.50 billion, a PE ratio of 65.18, a PEG ratio of 7.12 and a beta of 0.82. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.74. The firm's 50-day moving average price is $30.07 and its 200 day moving average price is $31.50. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same quarter last year, the firm earned $0.51 earnings per share. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.